C12N 2795/14133
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2795/14133 (Use of viral protein as therapeutic agent other than vaccine) appears on 9 US grants and 15 published applications in this corpus.
Search patents in C12N- Granted patents
- 9
- Published applications
- 15
- Assignees
- 8
- Inventors
- 20
- Latest grant
- 11 Mar 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 2 | 2 |
| 2017 | 1 | 3 |
| 2018 | 2 | 2 |
| 2019 | 1 | 0 |
| 2020 | 1 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 1 | 3 |
| 2024 | 0 | 0 |
| 2025 | 1 | 1 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- General amyloid interaction motif (GAIM)11 Mar 2025US 12,247,055 B2Amyl Therapeutics SRL
- General amyloid interaction motif (GAIM)4 Jul 2023US 11,692,017 B2Amyl Therapeutics SRL
- Fusion proteins comprising P3 of bacteriophage7 Jan 2020US 10,526,377 B2Proclara Biosciences, Inc.
- Fusion proteins comprising P3 of bacteriophage19 Feb 2019US 10,208,090 B2Proclara Biosciences, Inc.
- Bacteriophage gene 3 protein compositions and use as amyloid binding agents11 Dec 2018US 10,151,762 B2Proclara Biosciences, Inc.
- M13 bacteriophages displaying peptide motifs targeting amyloid-beta, methods and uses thereof19 Feb 2026US 2026/0048090 A1Universidade Do Minho
- Bacteriophages for Protection from Ultraviolet Irradiation1 May 2025US 2025/0134802 A1The Board of Trustees of the Leland Stanford Junior University
- Cancer eradicating - bio-nanoparticles (ce-bnp)2 Nov 2023US 2023/0346862 A1Athanor Biosciences, Inc.
- General amyloid interaction motif (gaim)7 Sep 2023US 2023/0279064 A1Amyl Therapeutics SRL
- Methods of treating or preventing a viral infection using bacteriophages23 Feb 2023US 2023/0059521 A1Atossa Therapeutics, Inc.
Most cited
By later US patents
- Bacteriophage gene 3 protein compositions and use as amyloid binding agents7US 9,493,515 B2Proclara Biosciences, Inc. · 2016
- Bacteriophage gene 3 protein compositions and use as amyloid binding agents5US 9,493,516 B2Proclara Biosciences, Inc. · 2016
- Bacteriophage gene 3 protein compositions and use as amyloid binding agents4US 9,688,728 B2Proclara Biosciences, Inc. · 2017
- Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity2US 9,988,444 B2Proclara Biosciences, Inc. · 2018
- General amyloid interaction motif (GAIM)1US 11,692,017 B2Amyl Therapeutics SRL · 2023